$AXON
AXON ENTERPRISE, INC.

2023 Q2 Form 10-Q Financial Statement

#000106918323000030 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $374.6M $343.0M
YoY Change 31.16% 33.78%
Cost Of Revenue $142.5M $138.9M
YoY Change 27.62% 37.99%
Gross Profit $232.1M $204.1M
YoY Change 33.43% 31.05%
Gross Profit Margin 61.96% 59.5%
Selling, General & Admin $119.9M $116.6M
YoY Change 26.23% 29.33%
% of Gross Profit 51.66% 57.11%
Research & Development $71.94M $70.93M
YoY Change 25.01% 46.49%
% of Gross Profit 30.99% 34.75%
Depreciation & Amortization $7.480M $6.689M
YoY Change 20.45% 16.23%
% of Gross Profit 3.22% 3.28%
Operating Expenses $191.9M $187.5M
YoY Change 25.77% 35.33%
Operating Profit $40.26M $16.61M
YoY Change 88.03% -3.41%
Interest Expense -$52.37M $25.28M
YoY Change -211.36% -54.29%
% of Operating Profit -130.08% 152.19%
Other Income/Expense, Net -$62.03M $15.61M
YoY Change
Pretax Income -$12.11M $41.88M
YoY Change -117.69% -42.22%
Income Tax -$24.53M -$3.255M
% Of Pretax Income -7.77%
Net Earnings $12.42M $45.14M
YoY Change -75.63% -17.74%
Net Earnings / Revenue 3.32% 13.16%
Basic Earnings Per Share $0.17 $0.62
Diluted Earnings Per Share $0.16 $0.61
COMMON SHARES
Basic Shares Outstanding 73.89M 72.86M
Diluted Shares Outstanding 75.78M 73.88M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $539.0M $318.2M
YoY Change 42.88% -28.32%
Cash & Equivalents $474.2M $263.4M
Short-Term Investments $64.80M $54.81M
Other Short-Term Assets $101.6M $142.3M
YoY Change 64.25% 111.76%
Inventory $249.8M $220.3M
Prepaid Expenses
Receivables $627.4M $596.8M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.113B $2.053B
YoY Change 80.6% 79.1%
LONG-TERM ASSETS
Property, Plant & Equipment $179.1M $172.7M
YoY Change 15.74% 15.5%
Goodwill $57.74M $44.98M
YoY Change 3.15%
Intangibles $21.84M $11.27M
YoY Change -21.73%
Long-Term Investments $249.1M $327.7M
YoY Change -18.75% 90.31%
Other Assets $177.9M $168.2M
YoY Change -13.09% 71.6%
Total Long-Term Assets $964.8M $955.3M
YoY Change 26.57% 52.51%
TOTAL ASSETS
Total Short-Term Assets $2.113B $2.053B
Total Long-Term Assets $964.8M $955.3M
Total Assets $3.077B $3.008B
YoY Change 59.28% 69.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $72.99M $65.99M
YoY Change 20.27% 33.72%
Accrued Expenses $118.2M $120.6M
YoY Change 24.96% 73.7%
Deferred Revenue $412.2M $408.1M
YoY Change 24.93%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $625.2M $616.1M
YoY Change 44.41% 30.9%
LONG-TERM LIABILITIES
Long-Term Debt $675.5M $674.7M
YoY Change
Other Long-Term Liabilities $2.843M $4.511M
YoY Change -99.07% -1.79%
Total Long-Term Liabilities $2.843M $4.511M
YoY Change -99.07% -1.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $625.2M $616.1M
Total Long-Term Liabilities $2.843M $4.511M
Total Liabilities $1.632B $1.605B
YoY Change 121.08% 147.81%
SHAREHOLDERS EQUITY
Retained Earnings $314.6M $302.2M
YoY Change 83.4%
Common Stock $1.293B $1.262B
YoY Change 12.8%
Preferred Stock
YoY Change
Treasury Stock (at cost) $155.9M $155.9M
YoY Change 0.0%
Treasury Stock Shares $20.22M
Shareholders Equity $1.445B $1.403B
YoY Change
Total Liabilities & Shareholders Equity $3.077B $3.008B
YoY Change 59.28% 69.71%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $12.42M $45.14M
YoY Change -75.63% -17.74%
Depreciation, Depletion And Amortization $7.480M $6.689M
YoY Change 20.45% 16.23%
Cash From Operating Activities $42.66M -$56.32M
YoY Change 120.15% -228.11%
INVESTING ACTIVITIES
Capital Expenditures $13.20M $8.513M
YoY Change -202.99% -50.21%
Acquisitions
YoY Change
Other Investing Activities $167.1M -$64.04M
YoY Change -195.16% -1043.51%
Cash From Investing Activities $153.9M -$72.67M
YoY Change -181.69% 602.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.26M 37.99M
YoY Change -1627.19% -2703.84%
NET CHANGE
Cash From Operating Activities 42.66M -56.32M
Cash From Investing Activities 153.9M -72.67M
Cash From Financing Activities 14.26M 37.99M
Net Change In Cash 210.9M -90.23M
YoY Change -224.03% -381.96%
FREE CASH FLOW
Cash From Operating Activities $42.66M -$56.32M
Capital Expenditures $13.20M $8.513M
Free Cash Flow $29.46M -$64.84M
YoY Change -8.5% -341.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Scottsdale
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85255
CY2023Q1 dei City Area Code
CityAreaCode
480
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
991-0797
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.00001 Par Value
CY2023Q1 dei Trading Symbol
TradingSymbol
AXON
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001069183
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71474581
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73874062
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-16391
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Axon Enterprise, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-0741227
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
17800 North 85th Street
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73885305
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263414000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
353684000
CY2023Q1 us-gaap Marketable Securities
MarketableSecurities
54810000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
39240000
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
775129000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
581769000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2029000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2176000
CY2023Q1 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
379887000
CY2022Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
358190000
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
216869000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
196902000
CY2023Q1 us-gaap Inventory Net
InventoryNet
220268000
CY2022Q4 us-gaap Inventory Net
InventoryNet
202471000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
142319000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73022000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
2052696000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1805278000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
172674000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
169843000
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
171122000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
156866000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11270000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12158000
CY2023Q1 us-gaap Goodwill
Goodwill
44982000
CY2022Q4 us-gaap Goodwill
Goodwill
44983000
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
31116000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
156207000
CY2023Q1 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
4467000
CY2022Q4 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
5210000
CY2023Q1 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
54886000
CY2022Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
45170000
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
296563000
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
296563000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
168173000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
159616000
CY2023Q1 us-gaap Assets
Assets
3007949000
CY2022Q4 us-gaap Assets
Assets
2851894000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
65988000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
59918000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
120607000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
155934000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
408061000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
360037000
CY2023Q1 axon Customer Deposit Current
CustomerDepositCurrent
13961000
CY2022Q4 axon Customer Deposit Current
CustomerDepositCurrent
20399000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7510000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6358000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
616127000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
602646000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
250366000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
248003000
CY2023Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
16198000
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
10745000
CY2023Q1 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
7983000
CY2022Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
6285000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35045000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37143000
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
674724000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
673967000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4511000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4613000
CY2023Q1 us-gaap Liabilities
Liabilities
1604954000
CY2022Q4 us-gaap Liabilities
Liabilities
1583403000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73874062
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71474581
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1262099000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1174594000
CY2023Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
20220227
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
20220227
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
155947000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
155947000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
302161000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
257022000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5319000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7179000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1402995000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1268491000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3007949000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2851894000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
343043000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
256426000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
138941000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
100687000
CY2023Q1 us-gaap Gross Profit
GrossProfit
204102000
CY2022Q1 us-gaap Gross Profit
GrossProfit
155739000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
116567000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90129000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70927000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48416000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
187494000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
138545000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
16608000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
17194000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
25276000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
55299000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
41884000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
72493000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3255000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17622000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
45139000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
54871000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.77
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.76
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72638000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70950000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73880000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72349000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
45139000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
54871000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1676000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1072000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
184000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-489000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46999000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53310000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1268491000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33650000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-34841000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54346000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34350000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
45139000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1860000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1402995000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1047849000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-70000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-1388000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25088000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
54871000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1561000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1124789000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
45139000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
54871000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6689000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5755000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
756000
CY2023Q1 axon Payment Of Coupon Interest
PaymentOfCouponInterest
863000
CY2023Q1 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-10000
CY2022Q1 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-40000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-146000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-106000
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
15570000
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
55851000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
34350000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
25088000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-9660000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
18029000
CY2023Q1 axon Provision For Unrecognized Tax Benefits
ProvisionForUnrecognizedTaxBenefits
855000
CY2022Q1 axon Provision For Unrecognized Tax Benefits
ProvisionForUnrecognizedTaxBenefits
1365000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-3890000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
159000
CY2023Q1 axon Non Cash Lease Expense
NonCashLeaseExpense
1395000
CY2022Q1 axon Non Cash Lease Expense
NonCashLeaseExpense
1556000
CY2023Q1 axon Credit Loss Reserve
CreditLossReserve
28000
CY2022Q1 axon Credit Loss Reserve
CreditLossReserve
228000
CY2023Q1 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
50431000
CY2022Q1 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-7495000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15811000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14260000
CY2023Q1 axon Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
64348000
CY2022Q1 axon Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
7074000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-37043000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-9580000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
50199000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
16037000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56323000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
43964000
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
145124000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
81088000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
7200000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8513000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17098000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
87000
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
125000
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
37000
CY2022Q1 axon Payments To Acquire Equity Securities Without Readily Determinable Fair Value
PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue
500000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72674000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10348000
CY2023Q1 axon Net Proceeds From Equity Offering
NetProceedsFromEquityOffering
33650000
CY2022Q1 axon Net Proceeds From Equity Offering
NetProceedsFromEquityOffering
-71000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
39181000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
34841000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1388000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37990000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1459000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
779000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-157000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-90228000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32000000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
355552000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
356438000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
265324000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
388438000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263414000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
386367000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1910000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2071000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
265324000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
388438000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
20936000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
334000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1130000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
888000
CY2023Q1 axon Receivables From Options Exercised
ReceivablesFromOptionsExercised
15165000
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
45139000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
54871000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72638000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70950000
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1242000
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1399000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73880000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72349000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.77
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.76
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7503000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2942000
CY2023Q1 axon Warranty Period After Purchase Of Product
WarrantyPeriodAfterPurchaseOfProduct
P1Y
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
811000
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2822000
CY2023Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
438000
CY2022Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1434000
CY2023Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
2928000
CY2022Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
116000
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3301000
CY2022Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1504000
CY2023Q1 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
5100000
CY2022Q4 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
4300000
CY2023Q1 axon Investments In Number Of Affiliates
InvestmentsInNumberOfAffiliates
8
CY2023Q1 axon Debt Instrument Principal Amount Denomination For Fair Value Calculation
DebtInstrumentPrincipalAmountDenominationForFairValueCalculation
1000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1900000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1900000
CY2023Q1 axon Short Term Investment
ShortTermInvestment
775129000
CY2023Q1 axon Long Term Investment
LongTermInvestment
31116000
CY2023Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
375600000
CY2023Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
375600000
CY2023Q1 axon Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Unrealized Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerUnrealizedLosses
17600000
CY2023Q1 axon Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Gross Unrealized Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerGrossUnrealizedLosses
600000
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification of Prior Year Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.</p>
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
343043000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
256426000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
343043000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
256426000
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
271755000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
658427000
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
133707000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
408061000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
250366000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
658427000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
360037000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
248003000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
608040000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
408061000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
250366000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
658427000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
360037000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
248003000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
608040000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
4800000000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1161037000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
107000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
36675000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1124469000
CY2023Q1 axon Cash Cash Equivalent And Investments Amortized Cost
CashCashEquivalentAndInvestmentsAmortizedCost
263414000
CY2023Q1 us-gaap Marketable Securities
MarketableSecurities
54810000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1183222000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
57000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
52379000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1130900000
CY2022Q4 axon Cash Cash Equivalent And Investments Amortized Cost
CashCashEquivalentAndInvestmentsAmortizedCost
353684000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
39240000
CY2022Q4 axon Short Term Investment
ShortTermInvestment
581769000
CY2022Q4 axon Long Term Investment
LongTermInvestment
156207000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3630000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
28000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
358000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3300000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2029000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2176000
CY2023Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1211000
CY2022Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1360000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
60000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
94000
CY2023Q1 axon Allowance For Expected Credit Losses On Customer Receivables
AllowanceForExpectedCreditLossesOnCustomerReceivables
3300000
CY2022Q4 axon Allowance For Expected Credit Losses On Customer Receivables
AllowanceForExpectedCreditLossesOnCustomerReceivables
3630000
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
86607000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
72740000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
133661000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
129731000
CY2023Q1 us-gaap Inventory Net
InventoryNet
220268000
CY2022Q4 us-gaap Inventory Net
InventoryNet
202471000
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
296563000
CY2021Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
83520000
CY2022Q1 axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
500000
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
0
CY2022Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
70432000
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
296563000
CY2022Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
154452000
axon Equity Securities Without Readily Determinable Fair Value Purchases
EquitySecuritiesWithoutReadilyDeterminableFairValuePurchases
129762000
axon Equity Securities Without Readily Determinable Fair Value Gain On Sale Of Securities
EquitySecuritiesWithoutReadilyDeterminableFairValueGainOnSaleOfSecurities
12312000
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
103890000
us-gaap Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
1485000
axon Equity Securities Without Readily Determinable Fair Value Exercises
EquitySecuritiesWithoutReadilyDeterminableFairValueExercises
66630000
axon Equity Securities Without Readily Determinable Fair Value Sales
EquitySecuritiesWithoutReadilyDeterminableFairValueSales
14546000
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
296563000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
63975000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
97882000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6840000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3861000
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3301000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
811000
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
7486000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
13559000
CY2023Q1 axon Accrued Inventory In Transit Current
AccruedInventoryInTransitCurrent
11318000
CY2022Q4 axon Accrued Inventory In Transit Current
AccruedInventoryInTransitCurrent
10548000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
27687000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29273000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
120607000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
155934000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
256426000
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
171100000
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
22300000
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
22300000
CY2023Q1 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
5000000.0
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.078
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
0.228
CY2023Q1 axon Effective Income Tax Rate Reconciliation Deduction Stockbased Compensation
EffectiveIncomeTaxRateReconciliationDeductionStockbasedCompensation
13000000.0
CY2018Q2 axon Market Capitalization Goal For Tranche First Tranche
MarketCapitalizationGoalForTrancheFirstTranche
2500000000
CY2018Q2 axon Market Capitalization Goal For Tranche Incremental Increase
MarketCapitalizationGoalForTrancheIncrementalIncrease
1000000000.0
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
343043000
CY2023Q1 axon Revenue Goal Goal Number One
RevenueGoalGoalNumberOne
710058000
CY2023Q1 axon Adjusted Ebitda Goal Goal Number One
AdjustedEbitdaGoalGoalNumberOne
125000000
CY2023Q1 axon Revenue Goal Goal Number Two
RevenueGoalGoalNumberTwo
860058000
CY2023Q1 axon Adjusted Ebitda Goal Goal Number Two
AdjustedEbitdaGoalGoalNumberTwo
155000000
CY2023Q1 axon Revenue Goal Goal Number Three
RevenueGoalGoalNumberThree
1010058000
CY2023Q1 axon Adjusted Ebitda Goal Goal Number Three
AdjustedEbitdaGoalGoalNumberThree
175000000
CY2023Q1 axon Revenue Goal Goal Number Four
RevenueGoalGoalNumberFour
1210058000
CY2023Q1 axon Adjusted Ebitda Goal Goal Number Four
AdjustedEbitdaGoalGoalNumberFour
190000000
CY2023Q1 axon Revenue Goal Goal Number Five
RevenueGoalGoalNumberFive
1410058000
CY2023Q1 axon Adjusted Ebitda Goal Goal Number Five
AdjustedEbitdaGoalGoalNumberFive
200000000
CY2023Q1 axon Revenue Goal Goal Number Six
RevenueGoalGoalNumberSix
1610058000
CY2023Q1 axon Adjusted Ebitda Goal Goal Number Six
AdjustedEbitdaGoalGoalNumberSix
210000000
CY2023Q1 axon Revenue Goal Goal Number Seven
RevenueGoalGoalNumberSeven
1810058000
CY2023Q1 axon Adjusted Ebitda Goal Goal Number Seven
AdjustedEbitdaGoalGoalNumberSeven
220000000
CY2023Q1 axon Revenue Goal Goal Number Eight
RevenueGoalGoalNumberEight
2010058000
CY2023Q1 axon Adjusted Ebitda Goal Goal Number Eight
AdjustedEbitdaGoalGoalNumberEight
230000000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
246000000.0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
500000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
34350000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
25088000
CY2023Q1 axon Debt Instrument Covenant Consolidated Leverage Ratio
DebtInstrumentCovenantConsolidatedLeverageRatio
0.78
CY2023Q1 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
4
CY2023Q1 axon Product Claims Self Insurance
ProductClaimsSelfInsurance
5000000.0
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
138941000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
100687000
CY2023Q1 us-gaap Gross Profit
GrossProfit
204102000
CY2022Q1 us-gaap Gross Profit
GrossProfit
155739000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70927000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48416000

Files In Submission

Name View Source Status
0001069183-23-000030-index-headers.html Edgar Link pending
0001069183-23-000030-index.html Edgar Link pending
0001069183-23-000030.txt Edgar Link pending
0001069183-23-000030-xbrl.zip Edgar Link pending
axon-20230331.xsd Edgar Link pending
axon-20230331x10q.htm Edgar Link pending
axon-20230331xex31d1.htm Edgar Link pending
axon-20230331xex31d2.htm Edgar Link pending
axon-20230331xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
axon-20230331_cal.xml Edgar Link unprocessable
axon-20230331_lab.xml Edgar Link unprocessable
axon-20230331_pre.xml Edgar Link unprocessable
axon-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
axon-20230331x10q_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending